Several mutations associated with imatinib resistance also confer resistance to one or more second-generation BCR-ABL inhibitors (bosutinib, dasatinib, or nilotinib). Each inhibitor has differing drug-resistance profiles and recommendations, based on the mutation status. GeneTAG has developed a comprehensive panel of iDDS probes for common drug-resistance mutations, including the "gatekeeper” BCR-ABL T315I mutation (which confers resistance to all three second-generation inhibitors, but is susceptible to the third-generation inhibitor ponatinib).
Our iDDS probe assays have competitive antiprobes, which block false-positives. This design feature enables unparalleled accuracy. For example, several probes in our CML drug-resistance panel accurately detected the target template, but not 6 closely related targets.